On March 31, 2026, Tonix Pharmaceuticals announced updates on its TNX-4800 product for Lyme disease, including information from Phase 1 trials presented on March 30, 2026. They plan to initiate a Phase 2 study in early 2027, targeting the prevention of Lyme disease with a 350 mg dose.